As investors waited Wednesday afternoon for Sarepta Therapeutics Inc.'s second-quarter earnings, news of a managed access program (MAP) with Clinigen Group plc's Idis division for Exondys 51 (eteplirsen) in Duchenne muscular dystrophy (DMD) had Wall Street speculating that the deal would add to fiscal-year 2017 guidance of more than $95 million.